LONDON — A U.Ok. well being company reiterated on Thursday that the restricted advantages of a pair of recent Alzheimer’s medicine don’t justify their excessive costs, which means the medicines received’t be made accessible by means of the Nationwide Well being Service.
The choice by the U.Ok.’s cost-effectiveness watchdog displays how well being authorities in numerous elements of the world have taken totally different approaches with the medicine, that are the primary to have proven they’ll sluggish the development of the illness however have stoked debate about simply how significant that progress is for sufferers and the way to weigh their accompanying dangers and prices.
The medicine — Eli Lilly’s Kisunla (often known as donanemab) and Biogen and Eisai’s Leqembi (lecanemab) — received approval from U.Ok. regulators final yr, with the Medicines and Healthcare merchandise Regulatory Company discovering the advantages of the medicine outweighed the dangers for sure sufferers.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
